Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02961790 · ClinicalTrials.gov registry record · Phase 3
Oxybutynin Chloride in Managing Hot Flashes
A Phase 3 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT02961790 is a Phase 3 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 150 participants.
The verdict
NCT02961790, a Phase 3 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects. ADAM-VTE
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Oxybutynin Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02961790
The ClinicalTrials.gov registry entry for NCT02961790 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02961790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02961790 about?
NCT02961790 is a clinical study titled "Oxybutynin Chloride in Managing Hot Flashes". This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior s...
What is the current status of trial NCT02961790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2016-12-09. Estimated completion is 2018-04-27.
What interventions are being tested in trial NCT02961790?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Questionnaire Administration (OTHER), Oxybutynin Chloride (DRUG).
Who is sponsoring clinical trial NCT02961790?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.